IQWiG reports in a preliminary review of data of Eklira Genuair/Bretaris Genuair (aclidinium bromide) from Almiral compared to Spiriva (tiotropium)...
Almirall has announced that the European Commission has granted marketing approval to Eklira/Bretaris Genuair(aclidinium 322�g twice daily) in all EU...
AstraZeneca has announced that Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission...
The EMA's CHMP has issued a positive opinion for the regulatory approval of Eklira (aclidinium), from Almirall, in all EU...
New Phase IIIb data demonstrates comparable efficacy for twice-daily Eklira Genuair (aclidinium bromide), from Almirall, vs tiotropium following the 6-week...
AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma).
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (see section 5.1).
Covis Pharma announced positive topline results from the AVANT phase III clinical trial for Duaklir (aclidinium bromide 400µg /formoterol 12µg twice-daily) and Eklira (aclidinium bromide 400µg twice-daily) – known as Tudorza in the U.S. This 24-week study achieved statistically significant and clinically important outcomes for all key endpoint measures of efficacy in adult patients with moderate to severe stable chronic obstructive pulmonary disease (COPD)
Full results of ATTAIN, a six month pivotal study of the efficacy and safety of Eklira/Bretairis (inhaled aclidinium), from Almirall,...